Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain.Trevena Inc is a clinical stage biopharmaceutical company. It discovers, develops and commercialize therapeutics that use a novel approach to target G protein coupled receptors.